PDCD1 and nasopharyngeal carcinoma: Notable examples include recently FDA-approved PD-1 targeting agents such as tislelizumab, used as monotherapy for unresectable or metastatic esophageal squamous cell carcinoma (ESCC) [21], and toripalimab, indicated for nasopharyngeal carcinoma (NPC).